Please login to the form below

Not currently logged in
Email:
Password:

belimumab

This page shows the latest belimumab news and features for those working in and with pharma, biotech and healthcare.

Biogen scores mid-stage trial win for lupus drug BIIB059

Biogen scores mid-stage trial win for lupus drug BIIB059

It has very few treatment options – the last treatment to be approved by the FDA was GlaxoSmithKline’s  Benlysta (belimumab) back in 2011, which ended a 50-year drought in new

Latest news

More from news
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Building a business that is lean and specialised Building a business that is lean and specialised

    The company was Human Genome Sciences and its acquirer, GlaxoSmithKline, had its eye on gaining full control of Benlysta (belimumab), the lupus product that the two had been co-marketing.

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....